A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care
Time to the first on-study SRE (non inferiority test)
until approximately 745 subjects have experienced at least one on-study SRE (anticipated to be approximately 34 months)
No
MD
Study Director
Amgen
Argentina: ANMAT (Administracion Nacional de Medicamentos Alimentos y Tecnologia Medica)
20050244
NCT00330759
June 2006
October 2011
Name | Location |
---|---|
Research Site | Alabaster, Alabama |
Research Site | Bentonville, Arkansas |
Research Site | Anaheim, California |
Research Site | Boulder, Colorado |
Research Site | Danbury, Connecticut |
Research Site | Lewes, Delaware |
Research Site | Boca Raton, Florida |
Research Site | Albany, Georgia |
Research Site | Boise, Idaho |
Research Site | Arlington Heights, Illinois |
Research Site | Bloomington, Indiana |
Research Site | Ashland, Kentucky |
Research Site | Baton Rouge, Louisiana |
Research Site | Bangor, Maine |
Research Site | Baltimore, Maryland |
Research Site | Battle Kreek, Michigan |
Research Site | Branson, Missouri |
Research Site | Las Vegas, Nevada |
Research Site | Hooksett, New Hampshire |
Research Site | Belleville, New Jersey |
Research Site | Albany, New York |
Research Site | Asheville, North Carolina |
Research Site | Akron, Ohio |
Research Site | Allentown, Pennsylvania |
Research Site | Charleston, South Carolina |
Research Site | Chattanooga, Tennessee |
Research Site | Abilene, Texas |
Research Site | Ivins, Utah |
Research Site | Abington, Virginia |
Research Site | Auburn, Washington |
Research Site | Clarksburg, West Virginia |